Patents by Inventor Isabel Cristina Gonzalez Valcarcel

Isabel Cristina Gonzalez Valcarcel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MAPT RNA interference agents
    Patent number: 11926827
    Abstract: Provided herein are MAPT RNAi agents and compositions comprising a MAPT RNAi agent. Also provided herein are methods of using the MAPT RNAi agents or compositions comprising a MAPT RNAi agent for reducing MAPT expression and/or treating tauopathy in a subject.
    Type: Grant
    Filed: May 3, 2023
    Date of Patent: March 12, 2024
    Assignee: ELI LILLY AND COMPANY
    Inventors: Barbara Calamini, Sarah Katharina Fritschi, Rebecca Ruth Miles, Andrew Peter McCarthy, Douglas Raymond Perkins, Keith Geoffrey Phillips, Kaushambi Roy, Isabel Cristina Gonzalez Valcarcel, Jibo Wang, Shih-Ying Wu, Jeremy S. York
  • MAPT RNA INTERFERENCE AGENTS
    Publication number: 20230340482
    Abstract: Provided herein are MAPT RNAi agents and compositions comprising a MAPT RNAi agent. Also provided herein are methods of using the MAPT RNAi agents or compositions comprising a MAPT RNAi agent for reducing MAPT expression and/or treating tauopathy in a subject.
    Type: Application
    Filed: May 3, 2023
    Publication date: October 26, 2023
    Inventors: Barbara Calamini, Sarah Katharina Fritschi, Rebecca Ruth Miles, Andrew Peter McCarthy, Douglas Raymond Perkins, Keith Geoffrey Phillips, Kaushambi Roy, Isabel Cristina Gonzalez Valcarcel, Jibo Wang, Shih-Ying Wu, Jeremy S. York
  • MAPT RNA INTERFERENCE AGENTS
    Publication number: 20230212576
    Abstract: Provided herein are MAPT RNAi agents and compositions comprising a MAPT RNAi agent. Also provided herein are methods of using the MAPT RNAi agents or compositions comprising a MAPT RNAi agent for reducing MAPT expression and/or treating tauopathy in a subject.
    Type: Application
    Filed: December 12, 2022
    Publication date: July 6, 2023
    Inventors: Barbara Calamani, Sarah Katharina Fritschi, Rebecca Ruth Miles, Andrew Peter McCarthy, Douglas Raymond Perkins, Keith Geoffrey Phillips, Kaushambi Roy, Isabel Cristina Gonzalez Valcarcel, Jibo Wang, Shih-Ying Wu, Jeremy S. York
  • Glucagon receptor antagonists, preparation and therapeutic uses
    Patent number: 7989457
    Abstract: The present invention discloses novel compounds of Formula (I), or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.
    Type: Grant
    Filed: May 13, 2005
    Date of Patent: August 2, 2011
    Assignee: Eli Lilly and Company
    Inventors: Mark Donald Chappell, Scott Eugene Conner, Isabel Cristina Gonzalez Valcarcel, Jason Eric Lamar, Jianke Li, Julie Sue Moyers, Rebecca Anne Owens, Allie Edward Tripp, Guoxin Zhu
  • Glucagon Receptor Antagonists, Preparation and Therapeutic Uses
    Publication number: 20080125468
    Abstract: The present invention discloses novel compounds of Formula (I), or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.
    Type: Application
    Filed: May 13, 2005
    Publication date: May 29, 2008
    Inventors: Mark Donald Chappell, Scott Eugene Conner, Isabel Cristina Gonzalez Valcarcel, Jason Eric Lamar, Jianke Li, Julie Sue Moyers, Rebecca Anne Owens, Allie Edward Tripp, Guoxin Zhu
  • Ppar modulators
    Publication number: 20060257987
    Abstract: The present invention is directed to a compound of formula I, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.
    Type: Application
    Filed: August 17, 2004
    Publication date: November 16, 2006
    Inventors: Isabel Cristina Gonzalez Valcarcel, Nathan Mantlo, Qing Shi, Minmin Wang, Leonard Winneroski, Yanping Xu, Jeremy York